AI Article Synopsis
- A study was conducted to see if the statin drug pravastatin could lower the chance of atrial fibrillation coming back after patients underwent electrical cardioversion (EC).
- 114 patients with atrial fibrillation lasting over 48 hours were divided into two groups: one receiving pravastatin (40 mg daily) for 9 weeks and the other receiving standard therapy without the drug.
- The results showed that pravastatin did not have any effect on reducing the recurrence rate of atrial fibrillation post-EC.
Article Abstract
To test the hypothesis that a statin could reduce the recurrence rate of atrial fibrillation after electrical cardioversion (EC), we performed an open, controlled multicenter study. Patients (n = 114) who had atrial fibrillation >48 hours and who were scheduled for EC were randomized to receive 40 mg of pravastatin once daily for 3 weeks before and 6 weeks after EC or no drug in addition to standard therapy. Pravastatin did not reduce the recurrence rate of atrial fibrillation after EC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2003.12.009 | DOI Listing |
Publication Analysis
Top Keywords
atrial fibrillation
16
fibrillation electrical
8
electrical cardioversion
8
reduce recurrence
8
recurrence rate
8
rate atrial
8
analysis pravastatin
4
pravastatin prevent
4
prevent recurrence
4
atrial
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!